Should I buy or sell Halozyme Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HALO shares. View HALO analyst ratings or view top-rated stocks .

What is Halozyme Therapeutics' stock price target for 2024?

11 equities research analysts have issued twelve-month target prices for Halozyme Therapeutics' shares. Their HALO share price targets range from $42.00 to $66.00. On average, they predict the company's stock price to reach $52.73 in the next twelve months. This suggests a possible upside of 32.0% from the stock's current price. View analysts price targets for HALO or view top-rated stocks among Wall Street analysts .

How have HALO shares performed in 2023?

Halozyme Therapeutics' stock was trading at $56.90 on January 1st, 2023. Since then, HALO shares have decreased by 29.8% and is now trading at $39.95. View the best growth stocks for 2023 here .

Are investors shorting Halozyme Therapeutics?

Halozyme Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 6,970,000 shares, an increase of 5.9% from the October 31st total of 6,580,000 shares. Based on an average trading volume of 875,400 shares, the short-interest ratio is presently 8.0 days. Approximately 5.3% of the shares of the company are short sold. View Halozyme Therapeutics' Short Interest .

When is Halozyme Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024. View our HALO earnings forecast .

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings results on Monday, November, 6th. The biopharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.02. The biopharmaceutical company earned $216.03 million during the quarter, compared to the consensus estimate of $219.47 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 190.74% and a net margin of 32.52%.

What ETFs hold Halozyme Therapeutics' stock?

ETFs with the largest weight of Halozyme Therapeutics (NASDAQ:HALO) stock in their portfolio include Future Fund Long/Short ETF (FFLS) , Future Fund Active ETF (FFND) , Invesco Biotechnology & Genome ETF (PBE) , Virtus LifeSci Biotech Products ETF (BBP) , BlackRock Future Innovators ETF (BFTR) , Invesco S&P MidCap 400 Pure Growth ETF (RFG) , SPDR S&P Biotech ETF (XBI) and Goldman Sachs Future Health Care Equity ETF (GDOC) .

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics issued an update on its FY23 earnings guidance on Monday, November, 6th. The company provided EPS guidance of $2.70-$2.80 for the period, compared to the consensus earnings per share estimate of $2.64. The company issued revenue guidance of $825-$845 million, compared to the consensus revenue estimate of $830.22 million.

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com . Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA) , Endologix (ELGX) , BlackRock (BLK) , Chipotle Mexican Grill (CMG) , Micron Technology (MU) , Gilead Sciences (GILD) , Athabasca Oil (ATH) , NIC (EGOV) , Allergan (AGN) and AbbVie (ABBV) .

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (5.85%), Northern Trust Corp (1.52%), Charles Schwab Investment Management Inc. (1.29%), Bank of New York Mellon Corp (0.99%), Allspring Global Investments Holdings LLC (0.67%) and Kennedy Capital Management LLC (0.49%). Insiders that own company stock include Connie Matsui , Helen Torley , James M Daly , Jean-Pierre Bizzari , Jeffrey William Henderson , Kenneth J Kelley , Matthew L Posard , Michael J Labarre and Nicole Labrosse . View institutional ownership trends .

How do I buy shares of Halozyme Therapeutics?

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Halozyme Therapeutics have any subsidiaries?

The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH. Read More

Halozyme Therapeutics (HALO) Stock Price, News & Analysis

$39.95

-0.20 (-0.50%)

(As of 12/8/2023 08:57 PM ET)

Compare

Today's Range: $39.47
▼
$41.06
50-Day Range: $33.32
▼
$40.86
52-Week Range: $29.85
▼
$59.40

Volume: 732,900 shs
Average Volume: 1.18 million shs
Market Capitalization: $5.28 billion

P/E Ratio: 21.25
Dividend Yield: N/A
Price Target: $52.73

Halozyme Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.73 Rating Score
Upside/Downside: 32.0% Upside
$52.73 Price Target
Short Interest: Bearish
5.33% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.12
Upright™ Environmental Score
News Sentiment: 1.40
Based on 9 Articles This Week
Insider Trading: Selling Shares
$756,200 Sold Last Quarter
Proj. Earnings Growth: 45.63%
From $2.52 to $3.67 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.03 out of 5 stars

Medical Sector

20th out of 942 stocks

Biological Products, Except Diagnostic Industry

2nd out of 157 stocks

3.4

Analyst's Opinion

Consensus Rating
Halozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $52.73, Halozyme Therapeutics has a forecasted upside of 32.0% from its current price of $39.95.
Amount of Analyst Coverage
Halozyme Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.33% of the float of Halozyme Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Halozyme Therapeutics has a short interest ratio ("days to cover") of 8.
Change versus previous month
Short interest in Halozyme Therapeutics has recently increased by 5.93%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Halozyme Therapeutics does not currently pay a dividend.
Dividend Growth
Halozyme Therapeutics does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Halozyme Therapeutics has received a 65.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Biopharmaceuticals" and "Medical technology engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for Halozyme Therapeutics is -1.12.

3.6

News and Social Media Coverage

News Sentiment
Halozyme Therapeutics has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Halozyme Therapeutics this week, compared to 4 articles on an average week.
Search Interest
Only 9 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.
MarketBeat Follows
7 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $756,200.00 in company stock.
Percentage Held by Insiders
Only 2.40% of the stock of Halozyme Therapeutics is held by insiders.
Percentage Held by Institutions
92.59% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

4.4

Earnings and Valuation

Earnings Growth
Earnings for Halozyme Therapeutics are expected to grow by 45.63% in the coming year, from $2.52 to $3.67 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Halozyme Therapeutics is 21.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 114.73.
Price to Earnings Ratio vs. Sector
The P/E ratio of Halozyme Therapeutics is 21.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 118.41.
Price to Earnings Growth Ratio
Halozyme Therapeutics has a PEG Ratio of 0.55. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Halozyme Therapeutics has a P/B Ratio of 31.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Halozyme Therapeutics Stock (NASDAQ:HALO)

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

HALO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HALO Stock News Headlines

December 6, 2023 | finance.yahoo.com

Why Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report?

November 19, 2023 | finance.yahoo.com

Halozyme Therapeutics' (NASDAQ:HALO) 20% CAGR outpaced the company's earnings growth over the same five-year period

December 11, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 17, 2023 | finance.yahoo.com

Insider Sell Alert: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of ...

November 16, 2023 | finance.yahoo.com

Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis

November 16, 2023 | finance.yahoo.com

Can Halozyme Therapeutics (HALO) Climb 28.72% to Reach the Level Wall Street Analysts Expect?

November 16, 2023 | seekingalpha.com

Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway

November 14, 2023 | morningstar.com

Halozyme Therapeutics Inc HALO

December 11, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 9, 2023 | seekingalpha.com

Halozyme Therapeutics Non-GAAP EPS of $0.75 beats by $0.04, revenue of $216M in-line

November 9, 2023 | msn.com

Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag

November 8, 2023 | finance.yahoo.com

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Call Transcript

November 8, 2023 | seekingalpha.com

Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript